Evoke制药 EVOK 深 沪
等待开盘 10-18 09:30:00 美东时间
4.46
-0.060
-1.33%
华盛通- 最 高4.73
- 今 开4.54
- 成交量 4.61万股
- 最 低 4.41
- 昨 收 4.52
- 总市值 695.09万
- 52周最高 12.3199
- 市盈率 静 --
- 换手率 2.96%
- 52周最低 1.94
- 委 比 -45.26%
- 总股本 155.85万
- 历史最高 2052.00
- 量 比 2.84
- 振 幅 7.08%
- 历史最低 1.94
- 每 手 1
- 风险率 1.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship
Evoke Pharma announced partnerships with Omnicell and Brentwood Pharmacy to expand access to GIMOTI, the only FDA-approved nasal spray for diabetic gastroparesis. These collaborations aim to enhance distribution through specialty pharmacies, nearly doubling the network and improving patient access. GIMOTI addresses a serious GI disorder affecting millions, offering relief via metoclopramide in a nasal spray form. The agreements with Omnicell and ...
08-26 11:00
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers ModivCare (NASDAQ:MODV) stock increased by 69.6% to $0.95 during Frida...
08-22 20:08
5 Healthcare Stocks On Fire This Week
Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech & pharma.
08-21 20:24
Market-Moving News for August 21st
WMT: -4% | Walmart shares are trading lower following mixed Q2 financial results. APM: 69% | DiamiR's APOE Genotyping Test Receives CLEP Approval From New York State Department Of Health EVOK: 53%
08-21 19:22
Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book
Evoke Pharma announced the listing of U.S. Patent No. 12,377,064 for GIMOTI® (metoclopramide) nasal spray in the FDA's Orange Book, covering its use for moderate to severe gastroparesis symptoms. The patent, expiring in November 2038, extends exclusivity beyond the previous patent's end date in May 2030. GIMOTI, a nasal spray for treating diabetic gastroparesis, provides a non-oral option addressing medication absorption issues. Evoke Pharma emph...
08-21 11:00
Evoke Pharma Q2 EPS $(0.62) Misses $(0.30) Estimate, Sales $3.752M Miss $3.796M Estimate
Evoke Pharma (NASDAQ:EVOK) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.30) by 106.67 percent. This is a 33.33 percent increase over losses of $(0.93) per share from
08-14 19:04
Evoke Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update
Evoke Pharma reported Q2 2025 net product sales of $3.8 million, up 47% year-over-year, driven by expanded pharmacy access and increased physician adoption. New prescribers grew 20% YoY. GIMOTI, their metoclopramide nasal spray, is seeing rising demand for treating diabetic gastroparesis. The company reaffirmed its full-year 2025 sales guidance of $16 million, reflecting strong market penetration and positive broader adoption. Evoke remains focus...
08-14 11:00
Evoke Pharma Secures New U.S. Patent For GIMOTI Nasal Spray Targeting Moderate To Severe Gastroparesis
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced the
08-06 18:37
【天风医药杨松团队|公司深度研究】科伦博泰生物：TROP2 ADC具备BIC潜力，全球多中心三期临床积极拓展
（来源：一棵大松树） 携手默沙东深耕TROP2ADC全球布局，具有BIC潜力 芦康沙妥珠单抗（SKB264）是公司自主研发的一款靶向...
08-06 15:27
Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038
Evoke Pharma has received U.S. Patent No. 12,377,064, extending GIMOTI®'s exclusivity to November 2038, nearly two additional years beyond the original 2036 projection. The patent covers the use of intranasal metoclopramide for treating moderate to severe gastroparesis symptoms, strengthening GIMOTI's intellectual property position. The company plans to list the patent in the FDA's Orange Book, enhancing its market protection. CEO Matt D’Onofrio ...
08-06 10:30
